id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-352159-qx16i7s1	Pettit, Natasha N.	Late Onset Infectious Complications and Safety of Tocilizumab in the Management of COVID‐19	2020-08-13		.txt	text/plain	3329	196	51	During the study period, the institutional guideline recommended administration of TCZ 400 mg intravenous once (with the option of redosing based on clinical response within 12-24 hours) if patients presented with severe and rapidly progressing hypoxia in addition to elevated inflammatory markers (e.g. D-Dimer >2 mg/L, C-reactive protein (CRP) >100mg/L, and/or ferritin >600 mcg/L (or >300mcg/L if ferritin doubled in the previous 24hrs)). To characterize the patients' clinical presentation, course, and outcomes in the group that received TCZ, we also evaluated time to TCZ from symptom onset, intensive care unit (ICU) admission at the time of the TCZ dose, the TCZ weight based dose, mechanical ventilation at the time of the TCZ dose, whether they also received remdesivir or a hydroxychloroquine based regimen, time to defervesce following TCZ (if the patient was febrile prior to the dose), time to positive culture (if they had positive cultures post TCZ), length of hospital stay (LOS), and mortality (all-cause).	./cache/cord-352159-qx16i7s1.txt	./txt/cord-352159-qx16i7s1.txt